Fig. 4
HIV-1 replication is reduced by administration of VX-765 in an animal model of infection. HIS mice were administered rFLT-3 L (50ug in 250ul PBS, 0.2 mg/mL) on days 0, 4 and 8, and infected with HIV-1ADA (10,000 ffu) on day 4. One group (HIV + VX, n = 6) was treated with VX-765 via intraperitoneal injection on days 4–14 and one group (HIV control, n = 7) was not treated. Bone marrow, blood, spleen, and LN were harvested on day 14 for analysis via histopathology and RNAScope in situ hybridization with probes specific to HIV-1 gag. Representative imaging acquired from whole slide scanning of (A) axillary LN or (B) spleen, in prepared sections cut from the widest area of the tissue. Quantification of the resulting images was performed using Qupath software to quantify total area positive for viral RNA in (C) the animals where sufficiently developed axillary LN could be isolated (HIV n = 3, HIV + VX n = 4), and (D) in spleen of all treated animals (HIV n = 7, HIV + VX n = 6). Data is shown as endpoints from individual animals, in addition to summarized data presented as mean ± SEM. Significant differences due to treatment were determined using an unpaired two tailed Student’s T-test. *p < 0.05